Very early researchLooking for participantsNCT05141474
What this trial is testing
Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Who this might be right for
Epithelial Tumors, MalignantMalignant Solid Tumor
Vall d'Hebron Institute of Oncology 10